2015
DOI: 10.1136/annrheumdis-2015-208073
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Objective To evaluate whether the classification of ANCA-associated vasculitis (AAV) patients according to ANCA type (anti-proteinase 3 [PR3] or anti-myeloperoxidase [MPO] antibodies) predicts treatment response. Methods Treatment responses were assessed among patients enrolled in the Rituximab in ANCA-associated Vasculitis trial according to both AAV diagnosis (granulomatosis with polyangiitis [GPA]/microscopic polyangiitis [MPA]) and ANCA type (PR3-AAV/MPO-AAV). Complete remission (CR) was defined as disea… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

9
131
1
12

Year Published

2016
2016
2022
2022

Publication Types

Select...
9

Relationship

2
7

Authors

Journals

citations
Cited by 207 publications
(153 citation statements)
references
References 23 publications
9
131
1
12
Order By: Relevance
“…Their observations contrast with those reported in other inflammatory conditions . While these differences may reflect differences between clinical trial cohorts and clinic‐based cohorts, our findings are consistent with the preponderance of data on other inflammatory conditions and data from a prior cross‐sectional study evaluating CVD risk in a small AAV cohort .…”
Section: Discussionsupporting
confidence: 81%
See 1 more Smart Citation
“…Their observations contrast with those reported in other inflammatory conditions . While these differences may reflect differences between clinical trial cohorts and clinic‐based cohorts, our findings are consistent with the preponderance of data on other inflammatory conditions and data from a prior cross‐sectional study evaluating CVD risk in a small AAV cohort .…”
Section: Discussionsupporting
confidence: 81%
“…conditions (5,25,26). While these differences may reflect differences between clinical trial cohorts and clinic-based cohorts, our findings are consistent with the preponderance of data on other inflammatory conditions (5,25,26) and data from a prior crosssectional study evaluating CVD risk in a small AAV cohort (21). Our findings add to a growing body of literature describing an inverse relationship between lipid levels and inflammation (5,25,26).…”
supporting
confidence: 86%
“…The optimal maintenance therapy with rituximab, the effectiveness of rituximab to prevent relapse, and the safety of rituximab treatment in Japanese patients with AAV remain to be established. Classification by ANCA subtype may be useful to guide the use of immunosuppression in AAV because patients with PR-3 ANCA vasculitis responded rituximab better than cyclophosphamide [30].…”
Section: Discussionmentioning
confidence: 99%
“…In the RAVE trial, a better response was seen in PR3 positive patients. 15 An alternative regimen of 1 gm given on two occasions 2 weeks apart has been widely used and shown to be as effective. 16 In the UK, rituximab may be used in AAV for primary induction in the following circumstances:…”
Section: Rituximabmentioning
confidence: 99%